Evidence map›Paper›PMID 42490934›Full record

ArticleFrontiers in immunology2026

Thrombotic thrombocytopenic purpura and macrophage activation syndrome secondary to Sjögren's syndrome: a case report.

Xiaoya Liu, Maiqi Liu, Mengjiao Yao, Haohu Wu, Lin Bian, Xiuhua Wang, Tingting Zhai, Qing Wang, Yanfeng Hou

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoya LiuThe First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, School of Clinical Medicine, Shandong First Medical University, Jinan, Shandong, China.
Maiqi LiuThe First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, School of Clinical Medicine, Shandong First Medical University, Jinan, Shandong, China.
Mengjiao YaoThe First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, School of Clinical Medicine, Shandong First Medical University, Jinan, Shandong, China.
Haohu WuThe First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, School of Clinical Medicine, Shandong First Medical University, Jinan, Shandong, China.
Lin BianDepartment of Rheumatology and Autoimmunology, Shandong Province University Clinical Immunology Translational Medicine Laboratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Xiuhua WangDepartment of Rheumatology and Autoimmunology, Shandong Province University Clinical Immunology Translational Medicine Laboratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Tingting ZhaiDepartment of Rheumatology and Autoimmunology, Shandong Province University Clinical Immunology Translational Medicine Laboratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Qing WangDepartment of Rheumatology and Autoimmunology, Shandong Province University Clinical Immunology Translational Medicine Laboratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Yanfeng HouDepartment of Rheumatology and Autoimmunology, Shandong Province University Clinical Immunology Translational Medicine Laboratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjögren's syndrome (SS) is a systemic autoimmune disorder frequently associated with diverse hematological manifestations. Immune-mediated thrombotic thrombocytopenic purpura (iTTP) and macrophage activation syndrome (MAS) represent rare, life-threatening complications, yet the consecutive occurrence of both conditions in the same SS patient is exceedingly rare. We report a 20-year-old female diagnosed with SS following drug-induced liver injury. In July 2023, she developed acute iTTP (0% ADAMTS13 activity, with positive inhibitory antibodies) shortly after the initiation of immunomodulatory therapy, which responded to plasma exchange and corticosteroids. In December 2023, following

Indexed as

Macrophage Activation SyndromePurpura, Thrombotic ThrombocytopenicSjogren's SyndromeFemaleHumansNitrilesPyrazolesYoung AdultNitrilesPyrazolesmacrophage activation syndromeplonmarlimabruxolitinibSjögren’s syndromethrombotic thrombocytopenic purpura

Identifiers

PMID42490934
PMCPMC13375717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.